mobile-logo
 

Pharmaceutical

Multiple Paths to Commercial Success
1

NEUROPATHIC PAIN

  • Replace opioids as a preferred analgesic for pain due to nerve damage or disease
2

OPIOID SPARING

  • Help resolve the opioid crisis − a candidate for expedited FDA approval
3

POST-TRAUMATIC STRESS DISORDER

  • Relieve the anxiety disorder stemming from frightening or disturbing life events
4

RETTSYNDROME – ORPHAN DRUG APPROVAL

  • Expedited FDA Approval ─ abridged requirements & market exclusivity.
  • Boosts prospects for acquisition by big pharma and others
5

SCHIZOPHRENIA

  • Effect of CBD on first episode schizophrenia patients – Pilot Study with Technion Israel
6

DIABETES

  • Liquid Structure CBD can suppress TNF-α and IL-6 cytokines and attenuate glycation to act as a therapeutic for controlling or reversing type 2 Diabetes

CBD FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER

ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a new clinical trial evaluating the efficacy of cannabidiol in ANANDA’s proprietary delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with traumatic brain injury. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial utilizing ANANDA’s proprietary Liquid StructureTM CBD.

READ MORE

CBD AND CHRONIC RADICULOPATHIC PAIN SYNDROMES

ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a second clinical trial to evaluate the effect of cannabidiol in ANANDA’s proprietary delivery technology on opioid sparing in participants with chronic radiculopathic pain syndromes maintained on opioid therapy. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial utilizing ANANDA’s proprietary Liquid StructureTM CBD.

READ MORE